However, the evidence for RAC1 and RAC1B in CRC therapy resistance is weak with only a few publications showing limited evidence for RAC1 and RAC1B in CRC chemotherapy resistance and one experiment relating RAC1B to cetuximab resistance. This evidence concerns the gene RAC1 and colorectal carcinoma.